InvestSource, Inc.: Hybred International, Inc. Shares Information About Product and Market

Jul 23, 2008 (M2 PRESSWIRE via COMTEX) -- THRX | Quote | Chart | News | PowerRating -- Stocks in the News: Hybred International, Inc.(OTCBB: HYII), Nutrition 21, Inc. (NASDAQ: NXXI), Opexa Therapeutics, Inc. (NASDAQ: OPXA), Theravance, Inc. (NASDAQ: THRX)

Jul 21, 2008 -- Hybred International, Inc.(OTCBB: HYII | Quote | Chart | News | PowerRating) was established in 2005 and became a publicly traded company earlier in Q1 2008. The Company believes it successfully created the next-generation therapeutic horseshoe and is pleased to share the following information. Corporate Web Site: www.hybredhorseshoe.com. About the Hybred Horseshoe: The Hybred Horseshoe was created to address the number one problem in the equine industry - hoof injuries which account for nearly 90% of all potentially serious and often detrimental injuries to horses employed in all sectors of the equestrian market. The Hybred Horseshoe is comprised of a polyurethane molding which once attached to an aluminum horse shoe thus becomes a shock absorber and protects the horse's hooves and joints from deterioration caused by running on hard surfaces such as concrete, asphalt and race tracks. In addition, its design features enable the farrier the use traditional shoeing methods. About the Equine Industry: The equine industry is approximately a $39 Billion industry according to a study published in 2005 by Deloitte Consulting LLP for the American Horse Council Foundation. Over 4.6 million people are engaged in the industry as horse owners, service providers, employees and volunteers; Tens of millions of other are spectators in equestrian events in one form or another.

The study also showed that the industry directly produces goods and services of $38.8 Billion, with a total impact of $101.5 Billion on the U.S. Gross Domestic Product. About the Horse Shoe Market: In the US alone, there are approximately 9 million horses that requiring shoeing each month. Considering that a shoeing is four horseshoes per horse each month for 9 million horses, the total horseshoe market in the United States is estimated at $432 million per annum. Based on the foregoing, the horse shoe industry, exclusive of any labor and tooling, is approximately $3.2 Billion a year. There are more than 52 million horses outside the United States, thus representing a potential market opportunity of an additional $18.7 Billion.

Jul 22, 2008 -- Nutrition 21, Inc. (NASDAQ: NXXI), a developer and marketer of nutritional supplements that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and address chronic joint pain, today announced its agreement with Walgreens to supply three new chromium picolinate products for the Finest Natural retail brand and one product for the Walgreens Gold Seal Private Label. These products are anticipated to be available late this summer or early fall. Walgreens, one of the largest retailers in the United States, has 6,300 stores in 49 states. "Walgreens commitment is a major milestone in our move to expand our retail nutrition supplement business by working with industry- moving retailers to meet the growing needs of health-conscious consumers," said Michael Fink, co-Chief Operating Officer of Nutrition 21. "It also reflects the growing appreciation by retailers of Nutrition 21's continuing commitment to develop and market proprietary and clinically substantiated nutraceuticals that address significant health care concerns. We anticipate beginning to receive revenues from these new products during the quarter ending September 30, 2008."

Jul 22, 2008 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company leading in the development of cell therapies for multiple sclerosis (MS) and diabetes, has completed an internal assessment of data from its Phase I/II two year extension study with Tovaxin in patients with MS. While confirming the favorable safety and efficacy profile of Tovaxin, further analysis also confirms both the benefit of consecutive annual treatments with Tovaxin and the advantage of tailoring each vaccination to the patient's changing disease profile. The extension study evaluated 22 intent-to-treat patients that had enrolled in two Phase I/II open-label clinical studies with Tovaxin. 13 patients were enrolled with Relapse Remitting Multiple Sclerosis (RRMS) and 9 with Secondary Progressive Multiple Sclerosis (SPMS). After the first annual course of treatment the company conducted an analysis of each patient's specific disease profile and myelin peptide epitope profile using Opexa's proprietary Epitope Analysis Assay (EAA). The analysis showed that 19 of the 22 patients (86%) had undergone an epitope shift, or change in disease pattern since the original course of treatment. Based on the epitope analysis, Opexa manufactured a new and specific vaccine for each of these patients for their second course of treatment. This enabled Opexa to tailor each vaccine to the individual's current disease profile, thereby maximizing the effect. "The results from this extension study support our clinical strategy for Tovaxin of annual treatments tailored to each patient's clinical disease state," commented Dr. Jim Williams, Opexa's Chief Operating Officer. "And although the safety and efficacy data from the two year Tovaxin studies are based on a limited MS patient sample across two open-label clinical studies, comparing the annualized relapse rates of the RRMS patient population treated with Tovaxin at 0.2, places this treatment at the lower end of documented relapse rates of the major marketed drugs which range from 0.2-0.9. We believe Tovaxin's safety profile and a treatment regimen of five subcutaneous injections per year will also position the therapy favorably from a patient compliance perspective," added Dr. Williams. The company is currently completing a larger Phase IIb study in 150 patients in a multi-center, randomized, double blind, and placebo-controlled study in patients with RRMS or Clinically Isolated Syndrome (CIS). The company expects to announce top line results in September 2008.

Jul 22, 2008 -- Theravance, Inc. (NASDAQ: THRX | Quote | Chart | News | PowerRating) announced today that the U.S. Food and Drug Administration (FDA) has not yet made a decision regarding the New Drug Application (NDA) for telavancin. The Prescription Drug User Fee Act (PDUFA) date for action by FDA was July 21, 2008, and as of that date, the company had not received an action letter from the FDA. Telavancin is a novel, bactericidal, once-daily injectable investigational antibiotic, for the proposed indication to treat complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The company previously announced that the FDA had indicated that it did not expect to take final action on the telavancin NDA prior to completing its further evaluation of study site monitoring and study conduct in the ATLAS Phase 3 program, nor prior to resolution of the manufacturing issues not specifically related to telavancin that were cited in the approvable letter received in October, 2007. "We continue to work diligently with the FDA to resolve the remaining issues on our cSSSI NDA," said Rick E Winningham, Chief Executive Officer of Theravance. "We remain confident in the data generated in this program and are committed to bringing the potential benefit of telavancin to those patients suffering from cSSSI and more serious infections such as hospital-acquired pneumonia."

Market Wrap for July 22nd, 2008

The stock market posted a solid gain on Tuesday, after a late-day surge led by the financial sector helped investors shrug off worse-than-expected earnings reports from major tech and financial firms. A drop in crude prices, thanks to the easing of a tropical storm threat, also helped bring buyers to the table. Tuesday looked like it was going to be an ugly session, as stocks opened 0.9% lower. But investors took the opportunity to buy the dip, encouraged by a drop in crude prices and a turnaround in financial stocks. The stock market ended the session with a gain of 1.4%, with six of the ten sectors posting a gain. Smaller-cap names played a large role in the broader market's strength, especially within the tech sector -- the tech-heavy Nasdaq Composite rose 1.1%, compared to the 0.1% rise of the large-cap Nasdaq 100. The Russell 2000 spiked 2.8%, benefiting from a 22% surge in airline stocks, thanks to a handful of better-than-expected reports and the drop in crude prices. Financials were at the center of the opening losses and the subsequent late-session rally. The sector fell 3.8% at the open after Wachovia (WB 16.80, +3.62) reported a larger-than-expected loss of $8.9 billion and American Express (AXP 38.12, -2.78) disappointed with its earnings and outlook. The financial sector is now up 31.5% in the last week. The industrial sector (+2.2%) also outperformed. General Electric (GE 28.51, +0.82) announced that it is partnering with Mubadala, an Abu Dhabi firm, on initiatives including commercial finance, and clean energy research and development. Each company will provide $4 billion in equity over the next three years.

Large-cap tech was a pocket of weakness, with Apple (AAPL 162.02, -4.27) and Texas Instruments (TXN 24.44, -4.08) slipping on their respective earnings/outlooks. Memory chip maker SanDisk (SNDK 13.62, -4.31) fell 24% on its earnings report. The tech sector underperformed with a loss of 0.1%, although this is a substantial improvement from its session low when it was down 2.0%. The energy sector (-2.2%) was a laggard, falling in conjunction with crude prices.

ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO TO: www.investsourceinc.com.

To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to www.ceo-corner.com This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation to buy or sell securities. InvestSource, Inc. has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by InvestSource, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this release have not given an opinion or approved the statements made in this release.

InvestSource, Inc. is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. InvestSource, Inc. affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. InvestSource, Inc. will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market. Please consult your broker before purchasing or selling any securities mentioned herein. InvestSource has agreed to be compensated 75,000 unrestricted shares of HYII for services rendered. To view full disclaimers, please go to http://investsourceinc.com/php/disclaimer.php (disclaimers).

CONTACT: InvestSource, Inc WWW: http://www.investsourceinc.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index